IMPORTANCE Age-related macular degeneration (AMD) is a leading cause of irreversible blindness among the elderly population globally. Currently, knowledge of the epidemiology of AMD in Australia remains scarce because of a paucity of recent population-based data.
A ge-related macular degeneration (AMD) is a leading cause of irreversible blindness among the elderly population in Australia 1,2 and other Western nations. 3, 4 The incidence of AMD is projected to increase with the aging of the population. 5 Studies have established that AMD severely affects quality of life 6, 7 and poses a significant financial burden, with estimated annual direct costs in Australia of $750 million. 8 Despite this, knowledge of the epidemiology of AMD in Australia remains scarce because of a paucity of recent national population-based data. This information is vital for effective policy formulation and planning for eye health care delivery in Australia.
A recent meta-analysis 9 of 39 population-based studies from around the world reported the pooled AMD prevalence (age range, 45-85 years) to be 0.37%. In Australia, 2 landmark, regional population-based cohort studies conducted in the early 1990s, the Melbourne Visual Impairment Project (VIP) (individuals ≥40 years of age) 10 and the Blue Mountains Eye Study (BMES) (individuals ≥49 years of age), 11 reported the prevalence of late AMD to be 0.68% (VIP) and 1.9% (BMES). Although these studies 10, 11 provided excellent insights into the burden of AMD in Australia, since their completion, there have been substantial demographic changes, including a marked increase in life expectancy and population growth. 12 There has been no national estimate of AMD in indigenous Australians. However, the National indigenous Eye Health Survey and the Central Australian Ocular Health Study reported that AMD is an uncommon cause of low vision in indigenous adults 40 years or older. 13, 14 Age-related macular degeneration was attributed as the main cause of vision loss in only 2% of cases in the National indigenous Eye Health Survey, whereas it was not the main cause of vision loss in any study participant in the Central Australian Ocular Health Study. The purpose of the present study was to examine the prevalence of AMD among nonindigenous and indigenous Australian adults in the National Eye Health Survey (NEHS).
Methods

Study Population
The NEHS is a nationwide, population-based survey conducted from March 11, 2015 , to April 18, 2016 , that investigated the prevalence and causes of vision impairment (<6/12 to ≥6/60 in the better eye) and blindness (<6/60 in the better eye) among nonindigenous Australians 50 years and older and indigenous Australians 40 years and older. The younger age criterion for indigenous participants was chosen because of the earlier onset and more rapid progression of common eye diseases and diabetes in indigenous Australians. 15 The sampling and testing methods have been desc ribed in detail elsewhere. 16, 17 
Interview and Examination Procedures
An interviewer-administered questionnaire was used to collect information on sociodemographic factors, ocular and medical histories, and previous use of eye health services. Participants underwent presenting distance visual acuity assessment using the logMAR chart, and automated refraction was performed (Nidek ARK-30 Type-R handheld auto-refractor/ keratometer, Nidek Co Ltd) on participants with vision loss of less than 6/12 that improved to 6/12 or greater with pinhole. Two standard, 45°, nonstereoscopic color retinal photographs were taken of each eye, one centered on the optic disc (field 1) and the other centered on the macula (field 2), using a Diabetic Retinopathy Screening nonmydriatic fundus camera (CenterVue SpA). Pupillary dilation was conducted when retinal images were of reduced quality because of small pupil size. A single experienced grader graded each image masked to the identity and clinical characteristics of study participants. Any uncertain cases were adjudicated by the study ophthalmologist.
Grading and Classification of AMD
Retinal images were deemed to be gradable for AMD if field 2 was present and two-thirds of the macular area was visible. A transparent grid was placed over field 2 of each eye and centered on the fovea. 19 The grid included 3 concentric circles with radii of 500, 1500, and 3000 μm and had 4 radial lines that divided the retinal image into superior, inferior, nasal, and temporal quadrants. Any AMD lesions outside the margins of this grid were excluded from analysis. 
Statistical Analysis
Data were weighted by calculating sample weights for all records using the probability of selection at each stage of sampling. The 95% CIs, taking into account the sampling design, were calculated for the prevalence of AMD. Univariate and multivariable multinomial logistic regression models were used to examine the associations between AMD severity (no AMD, early AMD, intermediate AMD, and late AMD) and key explanatory variables. Lack of multicollinearity between the independent variables in the model was verified. Statistical interaction was tested for all predictors of AMD in the final model. A plot of the residuals compared with estimates was examined to determine whether the assumptions of linearity and homoscedasticity were met. NLCHECK (Stata module) was used to check linearity assumption after model estimation. Adjusted proportions were calculated by logistic regression models, taking into account covariates and the sampling weight.
All analyses were performed by incorporating the sampling weights and nonresponse rate to obtain unbiased estimates from the complex NEHS sampling design. Analyses were conducted with Stata, version 14.2.0 (StataCorp). A 2-tailed P < .05 was considered to be statistically significant. [9.7] years for those with gradable images; P < .001). Of the total nonindigenous population with gradable retinal images for AMD, 1364 (46.3%) were male and 2121 (72.0%) identified as Oceanian. Of the indigenous participants with gradable retinal images for AMD, 274 (41.0%) were male. The age profiles of the nonindigenous and indigenous samples are presented in Figure 1 .
Results
A total of 4836 individuals were examined in the NEHS
Prevalence of AMD by Indigenous Status
The weighted prevalence among nonindigenous Australians 50 years and older was 14.8% (95% CI, 11.7%-18.6%) for early AMD and 10.5% (95% CI, 8.3%-13.1%) for intermediate AMD ( Table 1 ). The prevalence of individual AMD lesions, including soft drusen and pigment abnormalities, is given in Table 2 . Late AMD was found in 0.96% (95% CI, 0.59%-1.55%) of nonindigenous Australian adults, with atrophic AMD observed in 0.72% (95% CI, 0.41%-1.24%) and neovascular AMD in 0.24% (95% CI, 0.13%-0.47%). The weighted prevalence of late AMD increased with age in nonindigenous participants, with the following age-specific prevalences: 0.13% among those 69 years or older, 0.83% among those aged 70 to 79 years, and 6.7% among those 80 years or older (P < .001). Among nonindigenous Australians 50 years and older, the prevalence of late AMD was 1.4% for men and 0.61% for women (P = .02).
Among indigenous Australians 40 years and older, the weighted prevalence was 13.8% (95% CI, 9.7%-19.3%) for early AMD and 5.7% (95% CI, 4.7%-7.0%) for intermediate AMD. 
Discussion
This article presents the age-specific prevalence of early, intermediate, and late AMD in indigenous and nonindigenous Australian adults. We report the prevalence of late AMD among nonindigenous Australians (age range, 50-98 years) to be 0.96% and among indigenous Australians (age range, 40-92 years) to be 0.17%. Of importance, AMD was attributed as the main cause of bilateral blindness in approximately 70% of cases in the nonindigenous population. The overall prevalence of late AMD among nonindigenous participants was 0.96%, increasing 8-fold from 0.83% among those 70 to 79 years of age to 6.7% among those 80 years or older. A comparison of age-specific rates revealed that the prevalence of late AMD among nonindigenous participants was marginally higher than that reported in a recent global meta-analysis 9 of 39 population-based studies in the age category of 80 to 85 years (4.0% in the NEHS vs 3.3% globally).
In the Australian setting, we were able to compare the agestandardized prevalence of late AMD in our study with that reported in the Melbourne VIP. After age standardization, the prevalence of late AMD among nonindigenous participants in the present study (1.2%) was comparable to that reported in the Melbourne VIP (1.5%). Unlike the Melbourne VIP and BMES, a higher prevalence of late AMD was observed among male individuals. This finding is consistent with the Singapore Malay Eye Study 21 and the Los Angeles Latino Eye Study. 22 Given the well-recognized association between AMD and smoking, 23 this finding may reflect the higher smoking prevalence among men than women in Australia. 24 The ratio of atrophic to neovascular AMD is important to eye health service delivery because current therapy is available for only the neovascular form. Of interest, similar to findings from the Reykjavik Eye Study, 25 we report the ratio for atrophic vs neovascular AMD to be approximately 3:1. This finding is not consistent with findings from the Beaver Dam Eye Study, 26 the Rotterdam Eye Study, 27 and the BMES, 11 which reported that the ratio of neovascular type vs atrophic AMD was approximately 2:1. Additional studies are needed to elucidate this finding because of the small number of nonindigenous Australians with late AMD (n = 33) in the present study.
To enable more direct comparisons with the Melbourne VIP, the prevalence of early AMD was recalculated according to a synchronized definition in which early AMD included medium (63-to 125-μm) or large (>125-μm) drusen and/or associated hyperpigmentary or hypopigmentary abnormalities. After age standardization, we noted a higher prevalence of early AMD than in the Melbourne VIP participants among individuals 50 years and older (19.3% in VIP vs 26.1% in the NEHS). Extrapolating these findings to the current Australian population using 2011 census data, we estimated the number of nonindigenous Australian citizens 50 years and older to be 1.4 million with early AMD and 53 960 with late AMD. This is the first population-based study, to our knowledge, to report the national prevalence of AMD among indigenous Australians. The finding of a low rate of late AMD among indigenous participants (0.17%) is consistent with previous Australian studies 13, 14 that have reported that AMD is an uncommon cause of vision loss in indigenous adults. This finding is also consistent with earlier studies [28] [29] [30] 
Strengths and Limitations
The strengths of this study include its study and sampling design, large sample size, and stratification by indigenous status. A number of limitations must also be considered. First, there was a relatively small representation of the oldest age group in the sample, which may have resulted in an unstable estimate of late AMD. Second, several known and potential risk factors for AMD were not assessed, including family history, smoking history, blood pressure, alcohol consumption, and dietary intake, which limited our ability to conduct comprehensive risk factor analysis for AMD. Third, the use of nonstereoscopic images and the exclusion of optical coherence tomography in the study protocol may have resulted in a reduced sensitivity of AMD detection. Fourth, those with missing or ungradable images were on average older than study participants with gradable images, which may have led to an underestimation of the true prevalence of AMD among Australian adults.
Conclusions
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